RxDoctor Payments Data

Arun Ramachandran, MD

Sleep Medicine · Los Angeles, CANPI 1326332917

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,899 of the $16,791 with a category attached, or 94.7%. 12 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 53.3% of the total. Reporting peaked in 2021 at $9,117 and has fallen 99.7% since, to $29 in 2025.

$16,791in general payments, 2019–2025

Across 64 payments — averaging $262.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$9K
  • Biohaven Pharmaceutical Holding Company Ltd.$7K
  • AbbVie$340
  • Harmony Biosciences LLC$72
  • Teva Pharmaceuticals USA, Inc.$33
  • Novartis$33
  • plus $128 from 6 others

What the payments were for

  • Speaking & faculty fees$15,89995%
  • Food & beverage$8645%
  • Education$290%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,791 in reported general payments places this provider in the 85th percentile of 200 sleep medicine providers in California.

See all sleep medicine providers in California

Medicare billing

Part B allowed, 2024
$190,457
Medicare patients
388
Services billed
11,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl13$103,187
SunosiSolriamfetol Hcl39$55,102
Aimovig AutoinjectorErenumab-Aooe53$45,593
Nurtec OdtRimegepant Sulfate32$30,698
QuliptaAtogepant14$14,543
RytaryCarbidopa/Levodopa11$14,535
DayvigoLemborexant13$4,217
Fluticasone-VilanterolFluticasone/Vilanterol13$4,055
Pregabalin81$3,364
Modafinil49$3,155
Gabapentin106$2,145
Armodafinil34$1,497
RizatriptanRizatriptan Benzoate38$1,337
Sumatriptan Succinate40$1,209
Rosuvastatin Calcium11$1,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$72$103,18713 claims
AbbVieQulipta$340$14,54314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 200 sleep medicine providers in California.

Other sleep medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →